
|Videos|September 30, 2022
CHECKMATE 9ER: Quality of Life Outcomes
Author(s)Daniel J. George, MD
Dr Daniel J George talks about the quality-of-life outcomes from the CHECKMATE 9ER and how different metastatic scenarios might affect treatment selection.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























